Related Experiment Video
Updated: Jul 3, 2025
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review
Moksada Regmi1,2,3,4, Yingjie Wang1,2, Weihai Liu1,2,3
1Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, 100191, China.
Abstract:
In tumor therapeutics, the transition from conventional cytotoxic drugs to targeted molecular therapies, such as those targeting receptor tyrosine kinases, has been pivotal. Despite this progress, the clinical outcomes have remained modest, with glioblastoma patients' median survival stagnating at less than 15 months. This underscores the urgent need for more specialized treatment strategies. Our review delves into the progression toward immunomodulation in glioma treatment. We dissect critical discoveries in immunotherapy, such as spotlighting the instrumental role of tumor-associated macrophages, which account for approximately half of the immune cells in the glioma microenvironment, and myeloid-derived suppressor cells. The complex interplay between tumor cells and the immune microenvironment has been explored, revealing novel therapeutic targets. The uniqueness of our review is its exhaustive approach, synthesizing current research to elucidate the intricate roles of various molecules and receptors within the glioma microenvironment. This comprehensive synthesis not only maps the current landscape but also provides a blueprint for refining immunotherapy for glioma, signifying a paradigm shift toward leveraging immune mechanisms for improved patient prognosis.
Insights
This review explores advances in glioma immunotherapy, focusing on immune cells like tumor-associated macrophages. It highlights new therapeutic targets for improved glioblastoma treatment and patient survival.
Area of Science:
- Oncology
- Immunology
- Neuro-oncology
Background:
- Conventional glioblastoma treatments show limited efficacy, with median survival under 15 months.
- Targeted molecular therapies offer modest improvements, necessitating novel treatment strategies.
- The glioma microenvironment significantly influences treatment response.
Purpose of the Study:
- To review the progression of immunomodulation in glioma treatment.
- To dissect key discoveries in immunotherapy for glioma.
- To synthesize current research on the glioma immune microenvironment for therapeutic insights.
Main Methods:
- Comprehensive literature synthesis of immunotherapy research in glioma.
- Analysis of the roles of tumor-associated macrophages and myeloid-derived suppressor cells.
- Exploration of the tumor cell-immune microenvironment interplay.
Main Results:
- Tumor-associated macrophages constitute approximately 50% of immune cells in the glioma microenvironment.
- Myeloid-derived suppressor cells play a critical role in immune evasion.
- Complex interactions within the glioma microenvironment reveal novel therapeutic targets.
Conclusions:
- Immunotherapy represents a paradigm shift in glioma treatment.
- Understanding the glioma immune microenvironment is crucial for refining therapeutic strategies.
- Leveraging immune mechanisms holds promise for improving glioblastoma patient prognosis.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...